Deanne Miller - Immutep Insider

PRRUF -- USA Stock  

USD 0.02  0.00  0.00%

  Executive
Ms. Deanne Miller, LLB, serves as Chief Operating Officer, General Counsel, Company Secretary of Prima BioMed Ltd. Ms Miller has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima as General Counsel and Company Secretary in October 2012. She has a Combined Bachelor of Laws and Bachelor of Commerce, Accounting and Finance from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.
Age: 38  Executive Since 2016      
61 2 8315 7003  http://www.primabiomed.com.au
Miller has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal & Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima as General Counsel and Company Secretary in October 2012. She has a Combined Bachelor of Laws and Bachelor of Commerce, Accounting and Finance from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.

Management Efficiency

The company has return on total asset (ROA) of (18.59) % which means that it has lost $18.59 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (42.45) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 4.91 M in total debt with debt to equity ratio (D/E) of 19.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Immutep Limited has Current Ratio of 7.28 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 11 records

EXECUTIVE Since

Cristina GilFernandezMetro Pacific Investments Corpo
2013
Jiade LiuCHINA LIFE INSURANCE LTD
2015
Anna LlovidoMegaworld Corporation
2014
Qi RuanCHINA LIFE INSURANCE LTD
2016
Rolando SiatelaMegaworld Corporation
N/A
Yong ZhengCHINA LIFE INSURANCE LTD
2013
Joseph LacsonMetro Pacific Investments Corpo
2016
Zhong ZhanCHINA LIFE INSURANCE LTD
1968
Cheryll SerenoMegaworld Corporation
2018
Johann QuiazonMegaworld Corporation
2017
Mingguang LiCHINA LIFE INSURANCE LTD
2017

Entity Summary

Immutep Limited engages in the research, development, and commercialization of medical biotechnology products in Australia. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep is traded on OTC Market in USA.Immutep Limited (PRRUF) is traded on OTC Market in USA. It is located in 95 Pitt Street and employs 31 people.

Immutep Limited Leadership Team

Pete Meyers, Non-Executive Director
Russell Howard, Non-Executive Director
Larisa Chisholm, Bus. Devel. and Intellectual Property Manager
Tom Bloomfield, Joint Company Secretary
YueLing Wong, Non-Executive Deputy Chairman of the Board
Frederic Triebel, Chief Scientific Officer & Chief Medical Officer
Deanne Miller, General Counsel, Company Secretary
Sharron Gargosky, Chief Technical Officer
Grant Chamberlain, Non-Executive Director
Lucy Turnbull, Non-Executive Chairman of the Board
Marc Voigt, CEO, CFO, Chief Bus. Officer, Executive Director, Member of Audit and Risk Committee and Member of Remuneration Committee
Matthew Gregorowski, IR Contact Officer

Stock Performance Indicators

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Equity Analysis
Currently Active Assets on Macroaxis
CRM   
Purchased a lot of shares of
2 days ago
Traded for 156.0
CRM   
Purchased a lot of shares of
2 days ago
Traded for 156.0
F   
Purchased over 300 shares of
2 days ago
Traded for 9.81
C   
Purchased over 40 shares of
2 days ago
Traded for 74.735
GM   
Purchased over 70 shares of
2 days ago
Traded for 36.08
Additionally take a look at Your Equity Center. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.
Search macroaxis.com